Gastrointestinal Drugs Market

Gastrointestinal Drugs Market (Drug Class - Acid Neutralizers (Antacids, H2 Antagonists, and Proton Pump Inhibitors), Antidiarrheal and Laxatives, Antiemetic and Antinauseants, Anti-inflammatory Drugs, Biologics, and Antispasmodic; Route of Administration - Oral, Parenteral and Rectal; Disorder Type - Gastro-esophageal Reflux Disease, Inflammatory Bowel Disease, and Irritable Bowel Syndrome; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Gastrointestinal diseases are quite common all over the globe, and various treatments are available to tackle these health issues. One such way is the proper administration of a variety of drugs, thereby constituting a distinct gastrointestinal drugs market from a global perspective.

This market is mainly being driven due to rapidly progressing interests in research activities happening in drug development-based activities all over the globe. Moreover, cases of such ailments are quite common in old-aged people, and a rising geriatric population is also increasing the demand of such drugs. In addition, changing lifestyles, unhealthy eating habits, and increasing levels of stress also are key factors driving growth in the global gastrointestinal drugs market. With innovative advancements occurring in the techniques implemented for curing such issues at a steady pace, the global gastrointestinal drugs market is anticipated to register splendid revenue in the years to come.

As per expert analysts, the global gastrointestinal drugs market is foretold to clock revenue valuation of US$61.6 bn by 2024, which is a decent increase from an initial valuation of US$45.5 bn clocked in 2015. This growth is prophesized to occur at a healthy CAGR of 4.90% during the forecast period from 2016 to 2024.

gastrointestinal drugs market

Acid Neutralizers Come Out as Winning Segment in the Market

The global gastrointestinal drugs market is segregated into various segments on the basis of various criteria such as drug class, route of administration, disorder type, distribution channel, and regional spread. Under drug class, acid neutralizers, anti-diarrheal and laxatives, antiemetic and anti-nauseants, anti-inflammatory drugs, biologics, and antispasmodic, are key segments. Acid neutralizers are further subdivided into antacids, h2 antagonists, and proton pump inhibitors, in the form of sub-segments. In terms of administration route, oral, parenteral and rectal make up for the gastrointestinal drugs market. Under disorder type, gastro-esophageal reflux disease, inflammatory bowel disease, and irritable bowel syndrome, are prime illness types that require the administration of drugs. Whereas, the drugs are sold through three key distribution channels: hospital pharmacies, retail pharmacies, and online pharmacies.

Among all the drug classes, a rising demand for prevention of gastroesophageal reflux disease (GERD) has led to an increasing use of acid neutralizers. In this way, the acid neutralizers segment holds a dominant position in the global gastrointestinal drugs market. Moreover, the cost efficiency of such neutralizers too has contributed towards the segment’s splendid growth and presence in the market. Even in future, compared to other segments present under the drug class criteria, acid neutralizers are expected to continue gaining extensive revenue for the global gastrointestinal drugs market.

Region-wise, the global gastrointestinal drugs market is spread across North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa. Of these, North America occupies the primary slot in terms of revenue generation in the market. This is mainly due to the presence of favorable reimbursement policies in this region, which are highly beneficial for the welfare of those affected by gastrointestinal issues. Moreover, rapidly increasing instances of various chronic diseases, wherein gastrointestinal problems might exist as a key symptom, also is a prime factor responsible for the market’s progress in North America. To be specific, the region had registered a share of more than 41% in 2016, compared to other regions. With a surge in the number of old-aged people present in North America, the sales of gastrointestinal drugs are prophesized to rapidly increase in the near future.

In terms of the vendor landscape, Abbott Laboratories, Allergan Plc, AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., Sanofi, Takeda Pharmaceutical, and Valeant Pharmaceuticals Inc. are chief players operating in the global gastrointestinal drugs market.

Augmented Research and Development Activities to Boost Gastrointestinal Drugs Market

Gastrointestinal disorders are quite prevalent all over the world and there are a variety of medications and treatment methods available to address these health problems. One such method is proper drug administration, which has resulted in the development of a distinct gastrointestinal drugs industry on a global scale.  This factor is likely to favour development of the global gastrointestinal drugs market in the years to come.

This demand is primarily motivated by the increasingly growing interest in drug development-related research activities taking place all over the world. Furthermore, such diseases are very prevalent in the elderly, and the need for such medicines is growing as the geriatric population grows. In addition, evolving diets, unhealthy dietary patterns, and the stress levels are all contributing to the expansion of the global gastrointestinal drugs market. With constant developments in the procedures used to treat such problems, the global gastrointestinal drugs market is expected to grow significantly in the coming years.

High Prevalence of GI Problems in the Geriatric Population to Spur Market Growth

The rising prevalence of gastrointestinal diseases around the world is a major factor in the gastrointestinal drugs market's growth. On the other hand, heavy funding, especially in scientific research for the expansion and advancement of these medicines, as well as increasing awareness about the efficacy of the therapies as well as the healing process, are significantly contributing to the growth of the market. In addition, technical advancements in the treatment process are expected to propel this market forward significantly in the coming years. The demand for these drugs is expected to rise due to an increase in the number of patients struggling with GI disorders as a result of dietary changes.

North America is expected to become the world's most active geographic market for gastrointestinal medicines.  It is expected to gain a sizable chunk of the gastrointestinal drugs market in the coming years as a result of customer-friendly payment programmes for the treatment of chronic syndromes or diseases. Because of the increasing number of elderly people who are vulnerable to gastrointestinal diseases, North America is expected to maintain its dominance in the gastrointestinal drugs market.

The global gastrointestinal drugs market is segmented as follows: 

By Drug Class

  • Acid Neutralizers
    • Antacids
    • H2 antagonists
    • Proton pump inhibitors
  • Antidiarrheal and Laxatives
  • Antiemetic and Antinauseants
  • Anti-inflammatory drugs
  • Biologics
  • Others (Antispasmodic etc.) 

By Route of Administration

  • Oral
  • Parenteral
  • Rectal 

By Disorder Type

  • Gastro Esophageal Reflux Disease
  • Inflammatory Bowel Disease
  • Irritable Bowel Syndrome 

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies 

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
    • Southern Global
  • Middle East & Africa
    • GCC countries
    • South Africa
    • Rest of Middle East & Africa

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Gastrointestinal Drugs Market

    4. Market Overview
         4.1. Introduction
                4.1.1. Product Definition
                4.1.2. Industry Evolution / Developments
         4.2. Gastrointestinal Drugs Market Overview

    5. Market Dynamics
         5.1. Drivers
                5.1.1. Restraints
                5.1.2. Opportunity
                5.1.3. Trends 
         5.2. Porter’s Five Force Analysis
         5.3. FDA Approved Biologics Products
         5.4. Overview of Clinical Trials
         5.5. Epidemiology of Gastrointestinal Disease: Global Scenario
         5.6. Global prevalence of Inflammatory Bowel Disease in 2015

    6. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Drug Class
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Key Trends
         6.4. Market Size (US$ Mn) Forecast By Drug Class
                6.4.1. Acid Neutralizers
                          6.4.1.1. Antacids
                          6.4.1.2. H2 antagonists
                          6.4.1.3. Proton pump inhibitors
                          6.4.1.4. Helicobacter pylori eradication
                6.4.2. Antidiarrheal and Laxatives
                6.4.3. Antiemetic and Antinauseants
                6.4.4. Anti-inflammatory drugs
                6.4.5. Biologics
                6.4.6. Others (Antispasmodic etc.)
         6.5. Market Attractiveness By Drug Class

    7. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Route of Administration
         7.1. Introduction & Definition
         7.2. Key Findings / Developments
         7.3. Key Trends
         7.4. Market Size (US$ Mn) Forecast By Route of Administration
                7.4.1. Oral
                7.4.2. Intravenous
                7.4.3. Rectal
         7.5. Market Attractiveness By Route of Administration

    8. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Disorder Type
         8.1. Introduction & Definition     
         8.2. Key Findings / Developments
         8.3. Key Trends
         8.4. Market Size (US$ Mn) Forecast By Disorder Type
                8.4.1. Gastroesophageal Reflux Disease
                8.4.2. Inflammatory Bowel Disease
                8.4.3. Irritable Bowel Syndrome
         8.5. Market Attractiveness By Disorder Type

    9. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Distribution Channel
         9.1. Introduction & Definition
         9.2. Key Findings / Developments
         9.3. Key Trends
         9.4. Market Size (US$ Mn) Forecast By Distribution Channel
                9.4.1. Hospital Pharmacies
                9.4.2. Retail Pharmacies
                9.4.3. Online Pharmacies
         9.5. Market Attractiveness By Distribution Channel

    10. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Region
         10.1. Key Findings
         10.2. Policies and Regulations
         10.3. Market Size (US$ Mn) Forecast By Region
                10.3.1. North America
                10.3.2. Latin America
                10.3.3. Europe
                10.3.4. Asia Pacific
                10.3.5. Middle East and Africa
         10.4. Market Attractiveness By Country/Region

    11. North America Gastrointestinal Drugs Market Analysis and Forecast     
         11.1. Key Findings
         11.2. Policies and Regulations     
         11.3. Key Trends
         11.4. Market Value Forecast By Country
                11.4.1. US
                11.4.2. Canada
         11.5. Market Size (US$ Mn) Forecast By Drug Class
                11.5.1. Acid Neutralizers
                          11.5.1.1. Antacids
                          11.5.1.2. H2 antagonists
                          11.5.1.3. Proton pump inhibitors
                          11.5.1.4. Helicobacter pylori eradication
                11.5.2. Antidiarrheal and Laxatives
                11.5.3. Antiemetic and Antinauseants
                11.5.4. Anti-inflammatory drugs
                11.5.5. Biologics
                11.5.6. Others (Antispasmodic etc.)
         11.6. Market Size (US$ Mn) Forecast By Route of Administration
                11.6.1. Oral
                11.6.2. Intravenous
                11.6.3. Rectal
         11.7. Market Size (US$ Mn) Forecast By Disorder Type
                11.7.1. Gastroesophageal Reflux Disease
                11.7.2. Inflammatory Bowel Disease
                11.7.3. Irritable Bowel Syndrome
         11.8. Market Size (US$ Mn) Forecast By Distribution Channel
                11.8.1. Hospital Pharmacies
                11.8.2. Retail Pharmacies
                11.8.3. Online Pharmacies
         11.9. Market Attractiveness Analysis 
                11.9.1. By Country
                11.9.2. By Drug Class
                11.9.3. By Route of Administration
                11.9.4. By Disorder Type
                11.9.5. By Distribution Channel

    12. Europe Gastrointestinal Drugs Market Analysis and Forecast
         12.1. Key Findings
         12.2. Policies and Regulations
         12.3. Key Trends
         12.4. Market Value Forecast By Country
                12.4.1. Germany
                12.4.2. France
                12.4.3. U.K.
                12.4.4. Italy
                12.4.5. Russia
                12.4.6. Spain
                12.4.7. Rest of Europe
         12.5. Market Size (US$ Mn) Forecast By Drug Class
                12.5.1. Acid Neutralizers
                          12.5.1.1. Antacids
                          12.5.1.2. H2 antagonists
                          12.5.1.3. Proton pump inhibitors
                          12.5.1.4. Helicobacter pylori eradication
                12.5.2. Antidiarrheal and Laxatives
                12.5.3. Antiemetic and Antinauseants
                12.5.4. Anti-inflammatory drugs
                12.5.5. Biologics
                12.5.6. Others (Antispasmodic etc.)
         12.6. Market Size (US$ Mn) Forecast By Route of Administration
                12.6.1. Oral
                12.6.2. Intravenous
                12.6.3. Rectal
         12.7. Market Size (US$ Mn) Forecast By Disorder Type
                12.7.1. Gastroesophageal Reflux Disease
                12.7.2. Inflammatory Bowel Disease
                12.7.3. Irritable Bowel Syndrome
         12.8. Market Size (US$ Mn) Forecast By Distribution Channel
                12.8.1. Hospital Pharmacies
                12.8.2. Retail Pharmacies
                12.8.3. Online Pharmacies
         12.9. Market Attractiveness Analysis 
                12.9.1. By Country
                12.9.2. By Drug Class
                12.9.3. By Route of Administration
                12.9.4. By Disorder Type
                12.9.5. By Distribution Channel

    13. Asia Pacific Gastrointestinal Drugs Market Analysis and Forecast
         13.1. Key Findings
         13.2. Policies and Regulations
         13.3. Key Trends
         13.4. Market Value Forecast By Country
                13.4.1. China
                13.4.2. Japan
                13.4.3. India
                13.4.4. Australia & New Zealand
                13.4.5. India
                13.4.6. Rest of Asia Pacific
         13.5. Market Size (US$ Mn) Forecast By Drug Class
                13.5.1. Acid Neutralizers
                          13.5.1.1. Antacids
                          13.5.1.2. H2 antagonists
                          13.5.1.3. Proton pump inhibitors
                          13.5.1.4. Helicobacter pylori eradication
                13.5.2. Antidiarrheal and Laxatives
                13.5.3. Antiemetic and Antinauseants
                13.5.4. Anti-inflammatory drugs
                13.5.5. Biologics
                13.5.6. Others (Antispasmodic etc.)
         13.6. Market Size (US$ Mn) Forecast By Route of Administration
                13.6.1. Oral
                13.6.2. Intravenous
                13.6.3. Rectal
         13.7. Market Size (US$ Mn) Forecast By Disorder Type
                13.7.1. Gastroesophageal Reflux Disease
                13.7.2. Inflammatory Bowel Disease
                13.7.3. Irritable Bowel Syndrome
         13.8. Market Size (US$ Mn) Forecast By Distribution Channel
                13.8.1. Hospital Pharmacies
                13.8.2. Retail Pharmacies
                13.8.3. Online Pharmacies
         13.9. Market Attractiveness Analysis 
                13.9.1. By Country
                13.9.2. By Drug Class
                13.9.3. By Route of Administration
                13.9.4. By Disorder Type
                13.9.5. By Distribution Channel

    14. Latin America Gastrointestinal Drugs Market Analysis and Forecast
         14.1. Key Findings
         14.2. Policies and Regulations
         14.3. Key Trends
         14.4. Market Value Forecast By Country
                14.4.1. Brazil
                14.4.2. Mexico
                14.4.3. Rest of Latin America
         14.5. Market Size (US$ Mn) Forecast By Drug Class
                14.5.1. Acid Neutralizers
                          14.5.1.1. Antacids
                          14.5.1.2. H2 antagonists
                          14.5.1.3. Proton pump inhibitors
                          14.5.1.4. Helicobacter pylori eradication
                14.5.2. Antidiarrheal and Laxatives
                14.5.3. Antiemetic and Antinauseants
                14.5.4. Anti-inflammatory drugs
                14.5.5. Biologics
                14.5.6. Others (Antispasmodic etc.)
         14.6. Market Size (US$ Mn) Forecast By Route of Administration
                14.6.1. Oral
                14.6.2. Intravenous
                14.6.3. Rectal
         14.7. Market Size (US$ Mn) Forecast By Disorder Type
                14.7.1. Gastroesophageal Reflux Disease
                14.7.2. Inflammatory Bowel Disease
                14.7.3. Irritable Bowel Syndrome
         14.8. Market Size (US$ Mn) Forecast By Distribution Channel
                14.8.1. Hospital Pharmacies
                14.8.2. Retail Pharmacies
                14.8.3. Online Pharmacies
         14.9. Market Attractiveness Analysis 
                14.9.1. By Country
                14.9.2. By Drug Class
                14.9.3. By Route of Administration
                14.9.4. By Disorder Type
                14.9.5. By Distribution Channel

    15. Middle East & Africa Gastrointestinal Drugs Market Analysis and Forecast
         15.1. Key Findings
         15.2. Policies and Regulations
         15.3. Key Trends
         15.4. Market Value Forecast By Country
                15.4.1. GCC countries 
                15.4.2. South Africa
                15.4.3. Rest of Middle East & Africa
         15.5. Market Size (US$ Mn) Forecast By Drug Class
                15.5.1. Acid Neutralizers
                          15.5.1.1. Antacids
                          15.5.1.2. H2 antagonists
                          15.5.1.3. Proton pump inhibitors
                          15.5.1.4. Helicobacter pylori eradication
                15.5.2. Antidiarrheal and Laxatives
                15.5.3. Antiemetic and Antinauseants
                15.5.4. Anti-inflammatory drugs
                15.5.5. Biologics
                15.5.6. Others (Antispasmodic etc.)
         15.6. Market Size (US$ Mn) Forecast By Route of Administration
                15.6.1. Oral
                15.6.2. Intravenous
                15.6.3. Rectal
         15.7. Market Size (US$ Mn) Forecast By Disorder Type
                15.7.1. Gastroesophageal Reflux Disease
                15.7.2. Inflammatory Bowel Disease
                15.7.3. Irritable Bowel Syndrome
         15.8. Market Size (US$ Mn) Forecast By Distribution Channel
                15.8.1. Hospital Pharmacies
                15.8.2. Retail Pharmacies
                15.8.3. Online Pharmacies
         15.9. Market Attractiveness Analysis 
                15.9.1. By Country
                15.9.2. By Drug Class
                15.9.3. By Route of Administration
                15.9.4. By Disorder Type
                15.9.5. By Distribution Channel

    16. Competition Landscape
         16.1. Market Player 
         16.2. Company Share Analysis (2016)
         16.3. Company Profiles 
                16.3.1. Abbott Laboratories 
                          16.3.1.1. Overview
                          16.3.1.2. Financials
                          16.3.1.3. Recent Developments
                          16.3.1.4. Strategy
                16.3.2. Allergan Plc 
                          16.3.2.1. Overview
                          16.3.2.2. Financials
                          16.3.2.3. Recent Developments
                          16.3.2.4. Strategy
                16.3.3. AstraZeneca 
                          16.3.3.1. Overview
                          16.3.3.2. Financials
                          16.3.3.3. Recent Developments
                          16.3.3.4. Strategy
                16.3.4. Bayer AG 
                          16.3.4.1. Overview
                          16.3.4.2. Financials
                          16.3.4.3. Recent Developments
                          16.3.4.4. Strategy
                16.3.5. Boehringer Ingelheim GmbH 
                          16.3.5.1. Overview
                          16.3.5.2. Financials
                          16.3.5.3. Recent Developments
                          16.3.5.4. Strategy
                16.3.6. GlaxoSmithKline plc 
                          16.3.6.1. Overview
                          16.3.6.2. Financials
                          16.3.6.3. Recent Developments
                          16.3.6.4. Strategy
                16.3.7. Janssen Biotech, Inc. 
                          16.3.7.1. Overview
                          16.3.7.2. Financials
                          16.3.7.3. Recent Developments
                          16.3.7.4. Strategy
                16.3.8. Sanofi
                          16.3.8.1. Overview
                          16.3.8.2. Financials
                          16.3.8.3. Recent Developments
                          16.3.8.4. Strategy
                16.3.9. Takeda Pharmaceutical 
                          16.3.9.1. Overview
                          16.3.9.2. Financials
                          16.3.9.3. Recent Developments
                          16.3.9.4. Strategy
                16.3.10. Valeant Pharmaceuticals, Inc.
                          16.3.10.1. Overview
                          16.3.10.2. Financials
                          16.3.10.3. Recent Developments
                          16.3.10.4. Strategy

    List of Tables

    Table 01: Biologics Products, Manufacturers & Trade Names 
    Table 02: Biologics Products, Manufacturers & Trade Names 
    Table 03: Overview of major clinical trials for Inflammatory Bowel Disease
    Table 04: Overview of major clinical trials for Inflammatory Bowel Disease
    Table 05: Overview of major clinical trials for Inflammatory Bowel Disease
    Table 06: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
    Table 07: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizer (Drug Class), 2014–2024
    Table 08: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
    Table 09: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
    Table 10: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
    Table 11: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Region, 2014–2024
    Table 12: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
    Table 13: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
    Table 14: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014–2024
    Table 15: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
    Table 16: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
    Table 17: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
    Table 18: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
    Table 19: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
    Table 20: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014–2024
    Table 21: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
    Table 22: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
    Table 23: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
    Table 24: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
    Table 25: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
    Table 26: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class),
    Table 27: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
    Table 28: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
    Table 29: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
    Table 30: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
    Table 31: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
    Table 32: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014-2024
    Table 33: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
    Table 34: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
    Table 35: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
    Table 36: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
    Table 37: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
    Table 38: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers, 2014–2024
    Table 39: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
    Table 40: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
    Table 41: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024

    List of Figures

    Figure 01: Market Value Share, by Drug Class (2015)
    Figure 02: Market Value Share, by Route of Administration (2015)
    Figure 03: Market Value Share, by Disorder Type (2015)
    Figure 04: Market Value Share, by Distribution Channel (2015)
    Figure 05: Market Value Share, by Region (2015)
    Figure 06: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, 2014–2024
    Figure 07: Global Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
    Figure 08: Global Acid Neutralizers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 09: Global Antidiarrheal and Laxatives Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 10: Global Antiemetic and Antinauseants Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 11: Global Anti-inflammatory drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 12: Global Biologics Market Revenue (US$ Mn) and
    Figure 13: Global Others (Antispasmodic etc.)Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 14: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class
    Figure 15: Global Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
    Figure 16: Global Oral Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 17: Global Parenteral Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 18: Global Rectal Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 19: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
    Figure 20: Global Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
    Figure 21: Global Gastroesophageal Reflux Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 22: Global Inflammatory Bowel Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 23: Global Irritable Bowel Syndrome Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 24: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Disorder Type, 2016–2024
    Figure 25: Global Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
    Figure 26: Global Hospital Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 27: Global Retail Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 28: Global Online Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
    Figure 29: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Distribution Channel, 2016–2024
    Figure 30: Global Gastrointestinal Drugs Market Value Share Analysis, by Region, 2016 and 2024
    Figure 31: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Region
    Figure 32: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
    Figure 33: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
    Figure 34: North America Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
    Figure 35: North America Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
    Figure 36: North America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
    Figure 37: North America Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
    Figure 38: North America Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
    Figure 39: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
    Figure 40: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
    Figure 41: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Disorder Type, 2016–2024
    Figure 42: North America Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
    Figure 43: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
    Figure 44: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2015
    Figure 45: Europe Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
    Figure 46: Europe Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
    Figure 47: Europe Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
    Figure 48: Europe Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
    Figure 49: Europe Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
    Figure 50: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
    Figure 51: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
    Figure 52: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
    Figure 53: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
    Figure 54: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
    Figure 55: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
    Figure 56: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
    Figure 57: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
    Figure 58: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
    Figure 59: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
    Figure 60: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
    Figure 61: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
    Figure 62: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
    Figure 63: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
    Figure 64: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
    Figure 66: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
    Figure 67: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
    Figure 68: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
    Figure 69: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
    Figure 70: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
    Figure 71: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
    Figure 72: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
    Figure 73: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
    Figure 74: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
    Figure 75: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
    Figure 76: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
    Figure 77: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
    Figure 78: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
    Figure 79: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
    Figure 80: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
    Figure 81: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
    Figure 82: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
    Figure 83: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
    Figure 84: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
    Figure 85: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
    Figure 86: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
    Figure 87: Global Gastrointestinal Drugs Market Share Analysis, by Company, 2016 (Estimated)

Copyright © Transparency Market Research, Inc. All Rights reserved